Spots Global Cancer Trial Database for locally recurrent
Every month we try and update this database with for locally recurrent cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer | NCT02933944 | Rectal Cancer | TG02-treatment Pembrolizumab | 18 Years - | Targovax ASA | |
| An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy | NCT00686088 | Locally Recurre... | PRX302 | 18 Years - | Protox Inc. | |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | NCT00322400 | Locally Recurre... | Docetaxel Paclitaxel AMG 706 | 18 Years - | Amgen | |
| International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | NCT02051868 | Squamous Cell C... | Cisplatin 5-Fluorouracil ... Carboplatin Paclitaxel | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Post-Marketing Surveillance of Lenvima in Korean Patients | NCT02764554 | Differentiated ... | - | Eisai Inc. | ||
| Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer | NCT01269346 | Breast Cancer | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer | NCT02933944 | Rectal Cancer | TG02-treatment Pembrolizumab | 18 Years - | Targovax ASA | |
| International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | NCT02051868 | Squamous Cell C... | Cisplatin 5-Fluorouracil ... Carboplatin Paclitaxel | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | NCT01506609 | Metastatic Brea... | Placebo Veliparib Carboplatin Temozolomide Paclitaxel | 18 Years - | AbbVie | |
| A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | NCT01973309 | Metastatic Brea... | Vantictumab com... | 18 Years - 90 Years | Mereo BioPharma | |
| A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer | NCT01268150 | Locally Recurre... Metastatic Brea... | Eribulin mesyla... | 18 Years - | Eisai Inc. | |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | NCT02163694 | Metastatic Brea... | Veliparib Place... Veliparib Carboplatin Paclitaxel | 18 Years - | AbbVie |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
